ESDS Software IPO Day 2: GMP ₹355 (₹-10)
Welcome back, investors! We’re halfway through the ESDS Software IPO subscription period, and it’s time for our Day 2 update. The IPO, opening for subscription on August 28th and closing on September 1st, is for the mainboard listing on the NSE. With an issue price set at ₹429 per share, the market’s pulse is being closely watched. Today, we’ll dive into the subscription numbers, the latest Grey Market Premium (GMP) movement, and help you decide if this is an opportunity you shouldn’t miss.
| Date | GMP | Est. Listing |
|---|---|---|
| 03 Sep | +₹250 | ₹679 |
| 02 Sep | +₹250 | ₹679 |
| 01 Sep | +₹320 | ₹749 |
| 31 Aug | +₹370 | ₹799 |
| 29 Aug | +₹350 | ₹779 |
Subscription Status
As of the end of Day 2, the subscription figures for ESDS Software IPO are showing a complete lack of activity across all categories. We’re seeing 0x subscription for Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers), leading to a total subscription of 0x. This is quite unusual, especially by the second day of a mainboard IPO. Typically, by this stage, we’d expect at least some initial traction, even if it’s just from early birds in the retail segment. The absence of bids from QIBs and NIIs is particularly noteworthy. These are usually the big players who assess the fundamentals and market sentiment thoroughly before committing. Their silence could indicate a few things: perhaps they’re waiting for more data, or maybe they’re not yet convinced. For retail investors, this lack of immediate demand might seem concerning, but it could also present an opportunity to get in at a potentially attractive valuation if sentiment picks up later. The lot size for this IPO is 34 shares, meaning a single lot would cost ₹14,586 at the issue price.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 41.68x | |
| NII / HNI | 202.87x | |
| QIB | 274.97x | |
| Total | 274.97x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). The current GMP for ESDS Software IPO stands at ₹355. Yesterday, it was at ₹365. This represents a decrease of ₹10. While a dip in GMP is never ideal, it’s important to remember that GMP is a sentiment indicator, not a guarantee. The previous day’s GMP of ₹365 suggested a listing price expectation of around ₹784 (Issue Price ₹429 + GMP ₹355). The current GMP of ₹355 still points to a similar expected listing price of ₹784. The slight decrease might be due to the initial subdued subscription numbers, which can sometimes dampen market enthusiasm. However, a GMP of ₹355 is still substantial and indicates a strong interest from the grey market, suggesting that investors are willing to pay a significant premium over the issue price. It’s a positive sign that the expected listing price remains consistent, despite the minor GMP correction.
Should You Apply?
So, the big question: should you be applying for the ESDS Software IPO? Let’s break it down. The subscription numbers are currently a blank slate, which is definitely a point of caution. However, the GMP remains robust, indicating a healthy demand and a strong potential listing gain. The expected listing price of ₹784, derived from the issue price and GMP, presents an attractive proposition if it materializes. It’s crucial to remember that the IPO period extends until September 1st, and there’s still plenty of time for subscription numbers to pick up, especially in the final days. SEBI registered investment advisors often suggest looking at the company’s fundamentals, management quality, and future growth prospects alongside market sentiment indicators like GMP. If you’ve done your due diligence on ESDS Software’s business model and believe in its long-term potential, the current subdued subscription could be an opportunity to enter without facing intense competition. However, if you’re solely relying on listing gains and are wary of the current subscription silence, it might be prudent to wait and observe the trend in the coming days. The bottom line is, balance the lack of immediate subscription with the persistent strength in GMP and your own research into the company’s value.